LINANTA D 5/10

LINANTA D 5/10 is a dual-action therapy for effective management of type 2 diabetes mellitus. It contains Linagliptin 5 mg + Dapagliflozin 10 mg, working through complementary pathways to control blood glucose levels. Linagliptin enhances insulin secretion and reduces glucagon levels, while Dapagliflozin promotes urinary glucose excretion. This combination helps improve glycemic control, supports HbA1c reduction, and contributes to better overall metabolic balance in diabetic patients.